Adamax

Protocol examples

Protocol logic check

Independent evidence

Regulatory status: no approved label identified

Storage

No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Concurrent Semax use: Adamax is a pharmacokinetically superior derivative of Semax acting on identical TrkB/MC4R/BDNF targets; co-administration produces supraphysiological receptor agonism without incremental benefit while amplifying all stimulant-adjacent adverse effects and accelerating TrkB downregulation; these compounds are absolutely mutually exclusive.
• Severe anxiety disorders or active panic disorder: Adamax's enhanced CNS penetration amplifies the MC4R-driven dopaminergic activation and arousal effects of the Semax pharmacophore significantly beyond what parent Semax produces; subjects with anxiety disorders may experience pronounced worsening.
• Active manic episode or bipolar I disorder (manic phase): dopaminergic and noradrenergic amplification from high-CNS-penetrance MC4R agonism can trigger or accelerate manic states in susceptible individuals.
• Active psychotic disorders: contraindicated for the same reasons as Semax, with greater urgency given the amplified CNS potency.
• Late-day administration (after noon): the half-life of 1-2 hours means direct receptor activity clears reasonably quickly, but the BDNF transcription and MC4R-driven arousal effects persist several hours; evening administration reliably causes insomnia.
• Known hypersensitivity to Semax, Adamax, adamantane-modified peptides, or formulation excipients.
• Concurrent MAOI use: dopaminergic and serotonergic potentiation via MC4R creates serotonin/dopamine excess risk in the presence of monoamine oxidase inhibition.
• Pregnancy: no safety data; BDNF signaling plays critical roles in fetal neural development; exogenous supraphysiological BDNF stimulation in utero is not established as safe.
• Breastfeeding: no safety data.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Overstimulation: the most expected and dose-dependent adverse effect; characterized by racing thoughts, mental hyperactivity, inability to relax, mild euphoria at higher doses; a direct consequence of amplified MC4R-driven dopaminergic and noradrenergic tone from high CNS-penetrant delivery; managed with dose reduction or Selank co-administration.
• Insomnia: MC4R arousal activation persists several hours beyond the short plasma half-life; any administration after noon or at doses above individual tolerance reliably produces sleep onset difficulty; morning-only strict dosing is the primary management.
• Increased resting heart rate: mild tachycardia from adrenergic-adjacent MC4R activation; generally 5-10 BPM above baseline; typically well-tolerated but warrants monitoring.
• Anxiety and irritability: common at doses above individual tolerance; mechanistically identical to Semax anxiety but with greater intensity due to enhanced CNS delivery.
• Headache: reported in the initiation phase; possibly related to rapid changes in BDNF-driven cerebrovascular tone; typically self-limiting within the first week.
• Hair shedding (rare): BDNF elevation from Adamax, amplified relative to Semax, can accelerate hair follicle cycling and produce transient telogen effluvium; same mechanism as documented with Semax but potentially more pronounced.
• TrkB receptor downregulation: the primary long-term risk of sustained high-dose administration without adequate washout; results in diminished response to subsequent Adamax or Semax cycles; the 4-week washout protocol is the mitigation strategy.
• Nasal irritation: with intranasal administration specifically; not applicable to subcutaneous route.
• Mild blood pressure elevation: from adrenergic-adjacent MC4R/dopaminergic activation; rarely clinically significant at standard doses but warrants monitoring in subjects with cardiovascular risk factors.

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

Sources

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• PubMed search: Adamax